Back to top
more

Compugen Ltd. (CGEN)

(Delayed Data from NSDQ)

$8.96 USD

8.96
4,176,315

-1.40 (-13.51%)

Updated Feb 25, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum B VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 21% (199 out of 253)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Can Coronavirus Vaccine Efforts Aid BioNTech (BNTX) Q3 Earnings?

On BioNTech's (BNTX) upcoming Q3 earnings call, investors' focus will be on the progress and advancement of its COVID-19 vaccine candidate, currently being developed in partnership with Pfizer.

Insight Enterprises' (NSIT) Q3 Earnings Top Estimates, Up Y/Y

Insight Enterprises' (NSIT) Q3 performance benefits from acquisition of PCM amid sluggish demand from Asia Pacific and EMEA.

What Awaits AVEO Pharmaceuticals (AVEO) in Q3 Earnings?

On AVEO Pharmaceuticals' (AVEO) third-quarter earnings call, investor focus will be on the updates related to its NDA that seeks an approval for tivozanib to treat RCC in the United States.

What's in Store for ADMA Biologics' (ADMA) Q3 Earnings?

On ADMA Biologics' (ADMA) third-quarter earnings call, investor focus will be on the sales performance of its newly approved immunoglobulin products, Asceniv and Bivigam.

What's in Store for Selecta (SELB) This Earnings Season?

In absence of any marketed product, investor focus will be on Selecta's (SELB) efforts to develop its lead pipeline candidate SEL-212 during the third-quarter conference call.

Can Trikafta Drive Vertex's (VRTX) Revenues in Q3 Earnings?

On Vertex's (VRTX) third-quarter earnings call, investor focus will be on the sales performance of its triple combo CF drug Trikafta and the probable impact of COVID-19 on the same.

Is the Options Market Predicting a Spike in Compugen (CGEN) Stock?

Investors need to pay close attention to Compugen (CGEN) stock based on the movements in the options market lately.

How Compugen (CGEN) Stock Stands Out in a Strong Industry

Compugen (CGEN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Top Ranked Momentum Stocks to Buy for May 8th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, May 8th.

Compugen (CGEN) is a Great Momentum Stock: Should You Buy?

Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Compugen (CGEN) a New Strong Buy Stock

Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Top Ranked Momentum Stocks to Buy for April 30th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, April 30th.

Company News for Mar 10, 2020

Companies In The News Are: COCP, CGEN, AAPL, NINE

Ekta Bagri headshot

5 Biotech Stocks That Have More Than Doubled This Year

The biotech sector has had a good run in 2019 on the back of ongoing M&A activities and positive pipeline updates.

The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech

The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech

Indrajit Bandyopadhyay headshot

5 Biotech Stocks Up More Than 100% This Year So Far

The biotech sector recovers on the back of rising M&A activities and pipeline successes in 2019 after a dismal 2018. Here we discuss five biotech companies recording impressive growth.

Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) is a Great Choice

Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Compugen (CGEN) Upgraded to Buy: Here's What You Should Know

Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

MyoKardia Begins Dosing in Phase I Study on Heart Candidate

MyoKardia (MYOK) doses the first patient in phase I study on MYK-224, which is being evaluated for treating patients with hypertrophic cardiomyopathy, a common heart disease.

Vaccinex (VCNX) Attains Full Enrollment in Lung Cancer Study

Vaccinex (VCNX) completes enrollment in a phase Ib/II study of its pipeline candidate pepinemab in combination with Bavencio for treating advanced non-small cell lung cancer.

Mallinckrodt Enrolls First Patient in Liver Disease Study

Mallinckrodt (MNK) recruits the first patient in a mid-stage study on MNK-6106 for the treatment of hepatic cirrhosis and hepatic encephalopathy.

AMAG Q2 Loss Widens, Sales Lag Estimates, 2019 Guidance Cut

AMAG Pharmaceuticals (AMAG) reports wider-than-expected loss and sales miss in the second quarter of 2019. The company lowers its 2019 view.

Compugen (CGEN) Upgraded to Strong Buy: Here's What You Should Know

Compugen (CGEN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Compugen (CGEN) Upgraded to Buy: Here's What You Should Know

Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Compugen (CGEN) a New Strong Buy Stock

Compugen (CGEN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.